Blinatumomab in the treatment of adult acute lymphoblastic leukemia
MUDr. František Folber, Ph.D.
Interní hematologická a onkologická klinika, FN Brno a LF MU, Brno
Relapsed/refractory adult acute lymphoblastic leukemia is a serious clinical issue poorly manageable by the standard of care chemotherapy. Too many of these patients do not achieve a remission and survive only several months. Blinatumomab is a new promising immunotherapy drug targeting CD19 antigen present on a vast majority of B lineage adult acute lymphoblastic leukemia cells. Clinical trials have proven it to induce a remission more frequently compared to the standard treatment and thus such patients can proceed to an allogeneic transplant and take their chance towards a permanent cure. Adverse events are usually moderate and easily manageable. The major limiting factor for its use in a broader spectrum of patients is a very high market price, making blinatumomab the most expensive cancer drug on the market.
adult acute lymphoblastic leukemia, blinatumomab, treatment, clinical trials
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...